Compare Quest Diagnostics Inc (DGX) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hut 8 Corp — how do they compare? Quest Diagnostics Inc trades at $237.55 (market cap $26.21B), while Hut 8 Corp trades at $93.22 (market cap $10.94B). The key difference: Quest Diagnostics Inc is far larger — about 2.4× Hut 8 Corp's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| DGX | HUT | |
|---|---|---|
Market Cap | $26.21B | $10.94B |
Sector | Health | Technology |
52-Week High | $238.50 | $133.02 |
52-Week Low | $173.49 | $21.37 |
Enterprise Value | $31.97B | $18.38B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
HUT trades at $91.66, up 7.0% today amid a broader neocloud rally following NVIDIA's $500 billion AI pledge. The stock shows a bearish technical trend with support at $87 and resistance at $92. Fundamentally, Q2 2026 revenue grew 81% year-over-year to $74 million, but net losses widened to -$226 million in 2025. The company is transitioning to an AI data center platform, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (94%) targets $165.11, citing AI infrastructure potential, but high execution risks and persistent losses pose threats. Near-term volatility is likely as the market weighs Beacon Point commercialization progress against earnings misses and negative cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
